Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 9/20 | 0.36 |
| ▸ | HTR2A | P28223 | 6/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 7/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.34 |
| ▸ | DHPS | P49366 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449808 | 0.89 | DHPS (0.42) | DRD4HTR2AGPR119CHRM4DRD2 | |
| SCHEMBL449977 | 0.82 | HDAC1 (0.35) | DRD4GPR119DRD2HDAC1HDAC6 | |
| SCHEMBL449991 | 0.82 | HDAC1 (0.43) | HDAC1HDAC2 | |
| SCHEMBL450315 | 0.80 | MEN1 (0.39) | DRD4HTR2ADRD2HDAC1HDAC6 | |
| SCHEMBL2687336 | 0.79 | HDAC1 (0.41) | GPR119HDAC1HDAC2 | |
| SCHEMBL447315 | 0.77 | HDAC1 (0.55) | HDAC1HDAC2 | |
| SCHEMBL447034 | 0.77 | KDM4E (0.38) | DRD4HTR2ACHRM4DRD2HDAC1 | |
| SCHEMBL452168 | 0.76 | KDM4E (0.42) | HDAC1HDAC2MEN1KMT2A | |
| SCHEMBL650775 | 0.75 | HDAC1 (0.44) | GPR119HDAC1HDAC6HDAC2MEN1 | |
| SCHEMBL2134036 | 0.74 | CA2 (0.46) | GPR119HDAC1HDAC6HDAC2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716326-B2 | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-05-06 | — | — | US | disclosed |
| US-20120065396-A1 | ISOINDOLINONE DERIVATIVES, PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065396-A1 | ISOINDOLINONE DERIVATIVES, PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION COMPRISING SAME | PPIP5K2, SOST, ALPL | DRD4 2384/4885HTR2A 4255/4885GPR119 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.